Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Chordia Therapeutics Inc.. A complete text table follows the diagram.
The filing reports a development-stage cost base and a ¥633.703m net loss, with no operating revenue fact.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Reported business expenses | 1 | 663M | 100.0% of reported total |
| Pre-revenue biotech business expenses | 2 | 663M | Reported six-month total · ¥663M |
| Operating loss | 2 | 663M | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 1.3B | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| Reported business expenses | Pre-revenue biotech business expenses | 663M |
| Pre-revenue biotech business expenses | Operating costs & expenses | 663M |
| Operating loss | Operating costs & expenses | 663M |